ABSTRACT

Conclusion:

Our study demonstrated that the incidence of hypophosphatemia associated with FCM treatment in CKD patients was compatible with the rates in the literature. Clinicians should be careful in FCM treatment especially in patients having low baseline phosphorus level.

Results:

The average age of CKD group was 68.8±10.2 years (69% female). The average serum creatinin level and and estimated glomerular filtration rate were 2.3±1.1 mg/dL and 29.7±17.6 mL/min/1.73m², respectively. After the first week following FCM treatment, five of 11 patients in the control group (44.5%) and three of 32 patients in the CKD group (9.4%) developed hypophosphatemia (p=0.008). On linear regression analysis, it was found that baseline phosphorus level was the single predictor of hypophosphatemia (p=0.006).

Methods:

In our single center retrospective study, we included 43 adult patients who were given FCM therapy after nephrology clinic admission. Thirty-three non-dialysis CKD patients constituded the CKD group. Control group consisted of 11 patients with the diagnosis of iron deficiency anemia and normal renal function. Patients with missing data on serum phosphorus level before and after treatment were excluded.

Aim:

We aimed to find the incidence of hypophoshatemia and to investigate predictive factors for the development of hypophospahtemia in patients with chronic kidney disease (CKD) treated with intravenous ferric carboxymaltose (FCM).

References

Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9.

Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-16.

Astor BC, Muntner P, Levin A, Eustace JA, Coresh JA. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8.

Mcmurray JJV, Parfrey PS, Adamson JW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney inter Suppl 2012;2:279-335.

Geisser P. The pharmacology and safety profile of ferric carboxymaltose (Ferinject): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 2009;23:11-6.

Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung 2010;60:345-53.

Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49:2719-28.

Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Another form of FGF23-related hypophosphatemia. Bone 2009;45:814-6.

Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013;28:1793-803.

Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 2018;3:e124486.

Fierz YC, Kenmeni R, Gonthier A, Lier F, Pralong F, Coti Bertrand P. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr 2014;68:531-3.

Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation 2010;90:804-5.

Vandemergel X, Vandergheynst F. Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature. Case Rep Endocrinol 2014;2014:843689.

Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol 2017;83:1118-25.

Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35.

Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 2014;23:411-9.

Iguchi A, Kazama JJ, Yamamoto S, et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency. Nephron 2015;131:161-6.

Takeda Y, Komaba H, Goto S, et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011;33:421-6.

Yamashita K, Mizuiri S, Nishizawa Y, Kenichiro S, Doi S, Masaki T. Oral iron supplementation with sodium ferrous citrate reduces the serumintact and c-terminal FGF23 levels of maintenance hemodialysis patients. Nephrology (Carlton) 2016;22:947-53.

Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant 2018;33:1628-35.

Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS One 2016;11:e0167146.

Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant 2014;29:833-42.

Lysen-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 2009;69:739-56.

Hypophoshatemia Incidence in Patients with Chronic Kidney Disease Treated with Intravenous Ferric Carboxymaltose and Factors Related to Hypophosphatemia

ABSTRACT

References